Table S1. Table describing the hematological and serological profile of our patient with Alemtuzumab-induced neutropenia. Whole blood analysis, immunophenotypic analysis and serological analysis of parameters before, at the onset of neutropenia, throughout its duration and after neutropenia resolution. (DOCX 17 kb
Additional clinical characteristics of patients included in this study. Tables S1–S3 provide additio...
Figure S1. Dose-dependent ex vivo depletion of plasma cells by daratumumab in PBMC samples. (A) Repr...
Table S9. Correlation between STAT phosphorylation and HLA-E, HLA-ABC, and HLA-DR expression in diff...
Figure S1. Brain MRI scanning for our patient before and after Alemtuzumab initiation. Brain MRI sca...
Characteristics of enzyme-linked immunosorbent assays for plasma proteins. Table S2. Patient charact...
Data 3. Funnel plot of the meta-analysis of the risk of febrile neutropenia between outpatient vers...
Table S1. Comparison of levels of phosphorylated proteins between MS patients and controls in baseli...
Table S4. Comparison of levels of p38MAPK, Erk1/2, STAT1, and STAT6 between MS patients and controls...
Table S3. Comparison of levels of phosphorylated proteins between MS patients and controls after in ...
Table S1. Genomic analysis of pre-treatment tumor in complete responder with DLBCL. Table S2. Periph...
Data 2. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement. (DOC 63 k...
Additional file 1: Table S1. Antibodies used for flow cytometric analysis of PBMC. Table S2. Tabular...
Immunoglobulin levels following LCAR-B38M infusion. Levels of serum IgA, IgG, lambda chain, and kapp...
Table S2. Comparison of fold change of protein phosphorylation between MS patients and controls afte...
Complete blood counts at different time points during neutrophil depleting study. A White blood cell...
Additional clinical characteristics of patients included in this study. Tables S1–S3 provide additio...
Figure S1. Dose-dependent ex vivo depletion of plasma cells by daratumumab in PBMC samples. (A) Repr...
Table S9. Correlation between STAT phosphorylation and HLA-E, HLA-ABC, and HLA-DR expression in diff...
Figure S1. Brain MRI scanning for our patient before and after Alemtuzumab initiation. Brain MRI sca...
Characteristics of enzyme-linked immunosorbent assays for plasma proteins. Table S2. Patient charact...
Data 3. Funnel plot of the meta-analysis of the risk of febrile neutropenia between outpatient vers...
Table S1. Comparison of levels of phosphorylated proteins between MS patients and controls in baseli...
Table S4. Comparison of levels of p38MAPK, Erk1/2, STAT1, and STAT6 between MS patients and controls...
Table S3. Comparison of levels of phosphorylated proteins between MS patients and controls after in ...
Table S1. Genomic analysis of pre-treatment tumor in complete responder with DLBCL. Table S2. Periph...
Data 2. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement. (DOC 63 k...
Additional file 1: Table S1. Antibodies used for flow cytometric analysis of PBMC. Table S2. Tabular...
Immunoglobulin levels following LCAR-B38M infusion. Levels of serum IgA, IgG, lambda chain, and kapp...
Table S2. Comparison of fold change of protein phosphorylation between MS patients and controls afte...
Complete blood counts at different time points during neutrophil depleting study. A White blood cell...
Additional clinical characteristics of patients included in this study. Tables S1–S3 provide additio...
Figure S1. Dose-dependent ex vivo depletion of plasma cells by daratumumab in PBMC samples. (A) Repr...
Table S9. Correlation between STAT phosphorylation and HLA-E, HLA-ABC, and HLA-DR expression in diff...